{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T03:19:23Z","timestamp":1777605563893,"version":"3.51.4"},"reference-count":76,"publisher":"Informa UK Limited","issue":"5","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Pharmacotherapy"],"published-print":{"date-parts":[[2026,3,24]]},"DOI":"10.1080\/14656566.2026.2655418","type":"journal-article","created":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T06:59:30Z","timestamp":1775113170000},"page":"397-407","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":1,"title":["Treatment of giant cell arteritis: focus on upadacitinib"],"prefix":"10.1080","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7831-8738","authenticated-orcid":false,"given":"Wolfgang A.","family":"Schmidt","sequence":"first","affiliation":[{"name":"Waldfriede Hospital, Rheumatology","place":["Berlin, Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2026,4,13]]},"reference":[{"key":"e_1_3_6_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.24055"},{"key":"e_1_3_6_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2023.101847"},{"key":"e_1_3_6_5_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kem322"},{"key":"e_1_3_6_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-023-00976-8"},{"key":"e_1_3_6_7_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kead189"},{"key":"e_1_3_6_8_1","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X221149963"},{"key":"e_1_3_6_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaf367"},{"key":"e_1_3_6_10_1","unstructured":"Schmidt WA Alibone M Ludwig P et al. Frequency diagnosis and pharmacological treatment of giant cell arteritis in Germany \u2013 database analysis of medical insurance data. In press."},{"key":"e_1_3_6_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2020.07.005"},{"key":"e_1_3_6_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.30155"},{"key":"e_1_3_6_13_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-225134"},{"key":"e_1_3_6_14_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-215672"},{"key":"e_1_3_6_15_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-224543"},{"key":"e_1_3_6_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00393-024-01519-6"},{"key":"e_1_3_6_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2026.152945"},{"key":"e_1_3_6_18_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223480"},{"key":"e_1_3_6_19_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223296"},{"key":"e_1_3_6_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-022-00798-0"},{"key":"e_1_3_6_21_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223356"},{"key":"e_1_3_6_22_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2413449"},{"key":"e_1_3_6_23_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1613849"},{"key":"e_1_3_6_24_1","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0000000000001897"},{"issue":"9","key":"e_1_3_6_25_1","article-title":"Real world steroid burden, treatment patterns, and rheumatologists\u2019 perceptions on advanced therapy in giant cell arteritis [abstract]","volume":"77","author":"Dua A","year":"2025","unstructured":"Dua A, Kadakia A, Zueger P, et al. Real world steroid burden, treatment patterns, and rheumatologists\u2019 perceptions on advanced therapy in giant cell arteritis [abstract]. Arthritis Rheumatol. 2025;77(suppl 9).","journal-title":"Arthritis Rheumatol"},{"key":"e_1_3_6_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ard.2025.11.025"},{"key":"e_1_3_6_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.22754"},{"issue":"9","key":"e_1_3_6_28_1","article-title":"MEthotrexate versus TOcilizumab for treatment of Giant cell Arteritis (METOGiA trial): a multicenter, randomized, controlled trial [abstract]","volume":"77","author":"Samson M","year":"2025","unstructured":"Samson M, Bourredjem A, Outh R, et al. MEthotrexate versus TOcilizumab for treatment of Giant cell Arteritis (METOGiA trial): a multicenter, randomized, controlled trial [abstract]. Arthritis Rheumatol. 2025;77(suppl 9). Available from: https:\/\/acrabstracts.org\/abstract\/methotrexate-versus-tocilizumab-for-treatment-of-giant-cell-arteritis-metogia-trial-a-multicenter-randomized-controlled-trial\/","journal-title":"Arthritis Rheumatol"},{"key":"e_1_3_6_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2024.103716"},{"key":"e_1_3_6_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)00560-2"},{"key":"e_1_3_6_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-020-00227-2"},{"key":"e_1_3_6_32_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-023-03177-6"},{"key":"e_1_3_6_33_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2303452"},{"key":"e_1_3_6_34_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221126"},{"key":"e_1_3_6_35_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.15459"},{"key":"e_1_3_6_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(23)00032-2"},{"key":"e_1_3_6_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(24)00270-4"},{"key":"e_1_3_6_38_1","doi-asserted-by":"publisher","DOI":"10.5281\/zenodo.18693153"},{"key":"e_1_3_6_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ard.2026.01.009"},{"key":"e_1_3_6_40_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.40044"},{"key":"e_1_3_6_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(23)00101-7"},{"key":"e_1_3_6_42_1","doi-asserted-by":"publisher","DOI":"10.69645\/DQFX6833"},{"key":"e_1_3_6_43_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-203586"},{"key":"e_1_3_6_44_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-025-03493-z"},{"key":"e_1_3_6_45_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-146-9-200705010-00004"},{"key":"e_1_3_6_46_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221865"},{"key":"e_1_3_6_47_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.41774"},{"key":"e_1_3_6_48_1","unstructured":"Padda IS Bhatt R Patel P et al. Upadacitinib. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 [cited 2026 Feb 5]. Available from: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK572088\/"},{"key":"e_1_3_6_49_1","unstructured":"European Medicines Agency (EMA). Assessment report Rinvoq [Internet]. 2019 [cited 2026 Feb 5]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/rinvoq-epar-public-assessment-report_en.pdf"},{"key":"e_1_3_6_50_1","doi-asserted-by":"publisher","DOI":"10.1186\/s41927-018-0031-x"},{"key":"e_1_3_6_51_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13688"},{"key":"e_1_3_6_52_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keac203"},{"key":"e_1_3_6_53_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1187584"},{"key":"e_1_3_6_54_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-024-03314-9"},{"issue":"9","key":"e_1_3_6_55_1","article-title":"Efficacy and safety of upadacitinib in giant cell arteritis: 2-year results from the Re-randomized, double-blind SELECT-GCA phase 3 trial","volume":"77","author":"Schmidt W","year":"2025","unstructured":"Schmidt W, Setty A, Dejaco C, et al. Efficacy and safety of upadacitinib in giant cell arteritis: 2-year results from the Re-randomized, double-blind SELECT-GCA phase 3 trial. Arthritis Rheumatol [Internet]; 2025;77(suppl 9). Available from: https:\/\/acrabstracts.org\/abstract\/efficacy-and-safety-of-upadacitinib-in-giant-cell-arteritis-2-year-results-from-the-re-randomized-double-blind-select-gca-phase-3-trial\/","journal-title":"Arthritis Rheumatol"},{"key":"e_1_3_6_56_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2109927"},{"issue":"2","key":"e_1_3_6_57_1","first-page":"318","article-title":"The mechanism of action of tofacitinib - an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis","volume":"34","author":"Hodge JA","year":"2016","unstructured":"Hodge JA, Kawabata TT, Krishnaswami S, et al. The mechanism of action of tofacitinib - an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis. Clin Exp Rheumatol. 2016;34(2):318\u2013328.","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_3_6_58_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-220822"},{"key":"e_1_3_6_59_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.43188"},{"key":"e_1_3_6_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ard.2025.08.028"},{"key":"e_1_3_6_61_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.41095"},{"key":"e_1_3_6_62_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209773"},{"key":"e_1_3_6_63_1","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2024-005371"},{"key":"e_1_3_6_64_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-025-03328-y"},{"key":"e_1_3_6_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ard.2025.05.014"},{"key":"e_1_3_6_66_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ard.2025.01.018"},{"key":"e_1_3_6_67_1","doi-asserted-by":"publisher","DOI":"10.1055\/a-1074-7685"},{"key":"e_1_3_6_68_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-019-1837-7"},{"key":"e_1_3_6_69_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(21)00152-1"},{"key":"e_1_3_6_70_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(23)00265-5"},{"key":"e_1_3_6_71_1","doi-asserted-by":"publisher","DOI":"10.1093\/rap\/rkaf081"},{"key":"e_1_3_6_72_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2019.01.003"},{"key":"e_1_3_6_73_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kez091"},{"key":"e_1_3_6_74_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keab780"},{"key":"e_1_3_6_75_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaf450"},{"key":"e_1_3_6_76_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-025-03528-5"},{"key":"e_1_3_6_77_1","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics12010182"},{"key":"e_1_3_6_78_1","doi-asserted-by":"publisher","DOI":"10.1093\/mrcr\/rxaf050"}],"container-title":["Expert Opinion on Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14656566.2026.2655418","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T08:02:19Z","timestamp":1777017739000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14656566.2026.2655418"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,24]]},"references-count":76,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,3,24]]}},"alternative-id":["10.1080\/14656566.2026.2655418"],"URL":"https:\/\/doi.org\/10.1080\/14656566.2026.2655418","relation":{},"ISSN":["1465-6566","1744-7666"],"issn-type":[{"value":"1465-6566","type":"print"},{"value":"1744-7666","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,24]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2026-02-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-31","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-13","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}